Literature DB >> 18075249

Perseveration in Alzheimer's disease.

S Pekkala1, M L Albert, A Spiro, T Erkinjuntti.   

Abstract

BACKGROUND/AIMS AND METHODS: Perseveration is common in Alzheimer's disease (AD). We document the type and quantitative burden of perseveration as cognitive decline progresses from normal aging (n = 30) through mild AD (n = 20) to moderate AD (n = 20) by administering a semantic verbal fluency task.
RESULTS: We found perseveration to increase significantly with increasing severity of AD and different types of perseveration that distinguish the subject groups in a statistically significant manner. Recurrent and continuous perseverations appear early in AD. As the disease progresses in severity into moderate stage, the number of recurrent and continuous perseverations increases, and stuck-in-set perseverations emerge.
CONCLUSION: The different types of perseveration are likely to reflect the progressive deterioration of different brain regions in AD. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 18075249     DOI: 10.1159/000112476

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  12 in total

1.  Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.

Authors:  R B Gibbs; A M Chipman; R Hammond; D Nelson
Journal:  Horm Behav       Date:  2011-08-26       Impact factor: 3.587

2.  The neural correlates of motor intentional disorders in patients with subcortical vascular cognitive impairment.

Authors:  Geon Ha Kim; Sang Won Seo; Kihyo Jung; Oh-Hun Kwon; Hunki Kwon; Jong Hun Kim; Jee Hoon Roh; Min-Jeong Kim; Byung Hwa Lee; Doo Sang Yoon; Jung Won Hwang; Jong Min Lee; Jee Hyang Jeong; Heecheon You; Kenneth M Heilman; Duk L Na
Journal:  J Neurol       Date:  2015-10-29       Impact factor: 4.849

3.  Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment.

Authors:  Serguei V S Pakhomov; Lynn E Eberly; David S Knopman
Journal:  J Clin Exp Neuropsychol       Date:  2018-03-04       Impact factor: 2.475

4.  Untimed Design Fluency in Aging and Alzheimer's Disease: Psychometrics and Normative Data.

Authors:  Preeti Sunderaraman; Elisaveta Sokolov; Sarah Cines; Elizabeth Sullo; Aidan Orly; Bianca Lerer; Jason Karlawish; Edward Huey; Stephanie Cosentino
Journal:  Appl Neuropsychol Adult       Date:  2015-02-13       Impact factor: 2.248

5.  Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept).

Authors:  Carola Romberg; Mark P Mattson; Mohamed R Mughal; Timothy J Bussey; Lisa M Saksida
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

6.  Semantic verbal fluency in two contrasting languages.

Authors:  Seija Pekkala; Mira Goral; Jungmoon Hyun; Loraine K Obler; Timo Erkinjuntti; Martin L Albert
Journal:  Clin Linguist Phon       Date:  2009-06       Impact factor: 1.346

7.  Lexical retrieval in discourse: an early indicator of Alzheimer's dementia.

Authors:  Seija Pekkala; Debra Wiener; Jayandra J Himali; Alexa S Beiser; Loraine K Obler; Yulin Liu; Ann McKee; Sanford Auerbach; Sudha Seshadri; Philip A Wolf; Rhoda Au
Journal:  Clin Linguist Phon       Date:  2013-08-28       Impact factor: 1.346

8.  Exploration of verbal repetition in people with dementia using an online symptom-tracking tool.

Authors:  Emily Reeve; Pierre Molin; Amaris Hui; Kenneth Rockwood
Journal:  Int Psychogeriatr       Date:  2017-03-09       Impact factor: 3.878

9.  Analyzing Knowledge Retrieval Impairments Associated with Alzheimer's Disease Using Network Analyses.

Authors:  Jeffrey C Zemla; Joseph L Austerweil
Journal:  Complexity       Date:  2019-05-02       Impact factor: 2.833

10.  Coexistence of perseveration and apathy in the TDP-43Q331K knock-in mouse model of ALS-FTD.

Authors:  Eosu Kim; Matthew A White; Benjamin U Phillips; Laura Lopez-Cruz; Hyunjeong Kim; Christopher J Heath; Jong Eun Lee; Lisa M Saksida; Jemeen Sreedharan; Timothy J Bussey
Journal:  Transl Psychiatry       Date:  2020-11-04       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.